🇺🇸 FDA
Patent

US 10179819

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

granted A61KA61K2039/505A61K39/39558

Quick answer

US patent 10179819 (Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K39/39558, A61P, A61P35/00